文献速递造血干细胞移植与细胞治疗淋巴瘤

供者调节性B细胞(Bregs)水平高及其快速恢复与异基因造血干细胞移植后急性移植物抗宿主病(aGVHD)发生风险降低相关

High donor regulatory B cells (Bregs) and their rapid recovery are associated with protection from the development of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2025-08-11

本研究纳入24对接受未处理、完全HLA相合同胞供者异基因造血干细胞移植的血液恶性肿瘤供受者,评估供者外周血CD19+CD24hiCD38hi调节性B细胞(Breg)含量及移植后90天内Breg恢复率与aGVHD发生的相关性。结果显示,受者发生aGVHD的供者Breg频率和绝对数显著更低,aGVHD阳性患者第60天和第90天Breg恢复百分比显著降低,供者Breg中位数>1.85%可降低II-IV级aGVHD风险(HR=0.033,95%CI 0.002-0.477,p=0.012)。

要点

  • 受者发生aGVHD的供者Breg频率(p=0.005)和绝对数(p=0.016)显著更低。
  • aGVHD阳性患者第60天和第90天Breg恢复百分比显著低于aGVHD阴性患者(p<0.001和p=0.002)。
  • 供者Breg中位数>1.85%与II-IV级aGVHD风险降低相关(HR=0.033,95%CI 0.002-0.477,p=0.012)。

核心结论

  • 供者Breg含量高及其在allo-HSCT后90天内快速恢复与aGVHD发生风险降低相关。

研究设计与样本

  • 纳入24对接受未处理、完全HLA相合同胞供者异基因造血干细胞移植的血液恶性肿瘤供受者,评估供者外周血CD19+CD24hiCD38hi Breg含量及移植后90天内Breg恢复率与aGVHD的相关性。

主要发现

  • 受者发生aGVHD的供者Breg频率显著低于未发生aGVHD者(p=0.005),Breg绝对数亦显著更低(p=0.016)。
  • aGVHD阳性患者第60天Breg恢复百分比显著低于aGVHD阴性患者(p<0.001),第90天亦显著更低(p=0.002)。
  • 供者Breg中位数<1.85与aGVHD累积发生率更高相关(p=0.036);第30天、第60天和第90天Breg恢复中位数<1.92、<1.45和<1.36分别与aGVHD累积发生率更高相关(p=0.004和p=0.006)。
  • 多因素分析显示,输注移植物中Breg中位数>1.85%降低II-IV级aGVHD风险(HR=0.033,95%CI 0.002-0.477,p=0.012)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to evaluate the peripheral blood donor CD19+CD24hiCD38hi regulatory B-cell (Breg) content and the Breg recovery rates during 90 days following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their correlation with the development of acute graft-versus-host disease (aGVHD). Twenty-four donor-recipient pairs with hematological malignancies who underwent unmanipulated, fully HLA-matched allo-HSCT from related siblings were enrolled. The frequency of Bregs and their absolute number were significantly lower in donors whose recipients developed aGVHD (*p = 0.005 and *p = 0.016, respectively). Acute GVHD (+) patients had a significantly diminished percentages of Bregs recovered at days 60 and 90 compared to the aGVHD (-) ones (*p < 0.001 and *p = 0.002, respectively). A median donor Breg <1.85 as well as median Breg <1.92, <1.45, and <1.36 recovered on days 30, 60, and 90 were associated with a greater cumulative incidence of aGVHD (*p = 0.036, *p = 0.004 and *p = 0.006, respectively). Multivariate analysis revealed that infusion of grafts with a median Breg >1.85% decreased the risk of grades II-IV aGVHD (hazard ratio (HR) = 0.033, 95% confidence interval [CI] = 0.002-0.477; *p = 0.012). Our results revealed, for the first time, that high donor Breg content and their rapid recovery within 90 days after allo-HSCT were associated with a decreased risk of aGVHD.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ramzi M, Hesamadini M, Sanaei M, et al. High donor regulatory B cells (Bregs) and their rapid recovery are associated with protection from the development of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation. Br J Haematol. 2025. PMID: 40785639. doi:10.1111/bjh.70058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。